Mometasone
- Generic Name
- Mometasone
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30Cl2O6
- CAS Number
- 83919-23-7
- Unique Ingredient Identifier
- 04201GDN4R
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications.
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.
Mometasone furoate nasal spray is available both over-the-counter (OTC) and by prescription. The OTC nasal spray formulation of mometasone furoate is indicated for the treatment of upper respiratory allergic symptoms (e.g. rhinorrhea, sneezing) in patients ≥2 years of age. The prescription formulation is indicated for the treatment of chronic rhinosinusitis with nasal polyps in patients ≥18 year old and for the and prophylaxis of seasonal allergic rhinitis in patients ≥12 years old. It is also approved in combination with olopatadine for the symptomatic treatment of seasonal allergic rhinitis in patients ≥12 years.
- Associated Conditions
- Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Libbs Farmacêutica LTDA
- Target Recruit Count
- 32
- Registration Number
- NCT04271007
- Locations
- 🇧🇷
Dr Sérgio Sckalka, Osasco, São Paulo, Brazil
Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 313
- Registration Number
- NCT03882047
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Jeffrey Glassberg
- Target Recruit Count
- 80
- Registration Number
- NCT03758950
- Locations
- 🇺🇸
Mount Sinai St Luke's, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
- Conditions
- Nasal Polyps
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 414
- Registration Number
- NCT03085797
- Locations
- 🇬🇧
GSK Investigational Site, Rotherham, United Kingdom
Vasoconstriction Trial With LEO 90100 Aerosol Foam
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: LEO 90100 aerosol foamDrug: Dermoval®/Dermovate®Drug: DiprosoneDrug: EloconDrug: LocoidOther: LEO 90100 foam vehicle
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT02973776
- Locations
- 🇫🇷
CPCAD, Nice, Cedex, France
Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy
- Conditions
- Adenoidal Hypertrophy
- Interventions
- Drug: mometasone furoate + PlaceboDrug: mometasone furoateDrug: PlaceboDrug: Oxymetazoline + PlaceboDrug: Placebo + placeboDrug: mometasone furoate + Oxymetazoline
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Guangzhou Women and Children's Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT02559440
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2216
- Registration Number
- NCT02554786
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children
- Conditions
- Otitis Media With Effiusion
- Interventions
- Drug: MonteleukastDrug: Mometasone
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Hormozgan University of Medical Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT02541760
- Locations
- 🇮🇷
Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, Islamic Republic of
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 459
- Registration Number
- NCT02498509
- Locations
- 🇰🇷
Samsung Medical Center, Irwon-dong, Gangnam-gu, Seoul, Korea, Republic of
Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT02154334
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.